Search results
Results from the WOW.Com Content Network
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. [1] It was patented in 1967 and approved for medical use in 1972. [2]
fluorouracil (5-FU), epirubicin, cyclophosphamide: breast cancer: FEC-T fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere) breast cancer: FL (also known as Mayo) fluorouracil (5-FU), leucovorin (folinic acid) colorectal cancer: FLAG: fludarabine, cytarabine, G-CSF: relapsed or refractory acute ...
Fluorouracil (5-FU, 5-fluorouracil), sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. [3] By intravenous injection it is used for treatment of colorectal cancer , oesophageal cancer , stomach cancer , pancreatic cancer , breast cancer , and cervical cancer . [ 3 ]
Tegafur/uracil (abbreviation: UFT [1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer.. UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug) in a 4:1 molar ratio.
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
[23] [25] In the 5-FU clinical study cited above, people whose dose was adjusted to achieve a pre-determined target exposure realized an 84% improvement in treatment response rate and a six-month improvement in overall survival (OS) compared with those dosed by BSA. [23] 5-FU dose management avoids serious side effects experienced with BSA ...
In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. [1] Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence.